ANN ARBOR, Mich. — NanoBio Corp. announced Feb. 2 that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates.
“We are very pleased with this patent award in that the new claims circumscribe all of NanoBio’s anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants,” said James R. Baker Jr., NanoBio’s CEO and founder. “The timing of this allowance coincides nicely with several very important development milestones at NanoBio.”
NanoBio’s lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown promising results in a recently completed Phase 1 clinical study, the company said. It is in partnership discussions with several parties regarding NB-1008.
The development of the nanoemulsion platform began in the 1990s at the University of Michigan, and has since been supported by more than $110 million in grants, investments and partnership funding. The newly issued patent (U.S. #7,655,252) is licensed from the University of Michigan to NanoBio Corp. on an exclusive, worldwide basis. With this new patent, NanoBio now holds six U.S. patents and has filed more than 30 additional applications.
NanoBio Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat technology platform.